

Control of body size by SMA-5, a homolog of MAP kinase BMK1/ERK5, in *C. elegans*

Naoharu Watanabe¹, Yasuko Nagamatsu¹, Keiko Gengyo-Ando², Shohei Mitani² and Yasumi Ohshima^{1,*†}

¹Department of Biology, Faculty of Sciences, Kyushu University Graduate School, Hakozaki, Fukuoka 812-8581, Japan

²Department of Physiology, Tokyo Women's Medical University School of Medicine, Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan

*Present address: Department of Applied Life Science, Faculty of Biotechnology and Life Science, Sojo University, 4-22-1, Ikeda, Kumamoto-city 860-0082, Japan

†Author for correspondence (e-mail: ohshima@life.sojo-u.ac.jp)

Accepted 9 May 2005

Development 132, 3175-3184

Published by The Company of Biologists 2005

doi:10.1242/dev.01895

Summary

We have analyzed the *sma-5(n678)* mutant in *C. elegans* to elucidate mechanisms controlling body size. The *sma-5* mutant is very small, grows slowly and its intestinal granules look abnormal. We found a 15 kb deletion in the mutant that includes a 226 bp deletion of the 3' end of the W06B3.2-coding sequence. Based on this result, rescue experiments, RNAi experiments and a newly isolated deletion mutant of W06B3.2, we conclude that W06B3.2 is the *sma-5* gene. The *sma-5* mutant has much smaller intestine, body wall muscles and hypodermis than those of the wild type. However, the number of intestinal cells or body wall muscle cells is not changed, indicating that the *sma-5* mutant has much smaller cells. In relation to the smaller cell size, the amount of total protein is drastically

decreased; however, the DNA content of the intestinal nuclei is unchanged in the *sma-5* mutant. The *sma-5* gene is expressed in intestine, excretory cell and hypodermis, and encodes homologs of a mammalian MAP kinase BMK1/ERK5/MAPK7, which was reported to control cell cycle and cell proliferation. Expression of the *sma-5* gene in hypodermis is important for body size control, and it can function both organ-autonomously and non-autonomously. We propose that the *sma-5* gene functions in a MAP kinase pathway to regulate body size mainly through control of cell growth.

Key words: Body size, MAP kinase, *C. elegans*, SMA-5

Introduction

There are many studies on the size of an animal or a plant in the literature. For example, mice that overexpressed growth hormone became larger (Palmiter et al., 1982), and in *Dictyostelium*, *smlA* mutant cells oversecrete a factor to form very small fruiting bodies (Brock and Gomer, 1999). In *Drosophila*, mutants in the components of the insulin/insulin-like growth factor 1 (IGF1) signaling pathway have been reported to be smaller (Leevers et al., 1996; Böhni et al., 1999). Many factors known to control body size or growth in various animals are involved in insulin/insulin-like growth factor signaling as described above, or TGF β signaling (Patterson and Padgett, 2000; Massague, 2000), suggesting that they are major and conserved signal pathways controlling body size. However, the mechanisms of body size determination are largely unknown (Conlon and Raff, 1999).

C. elegans is an excellent model animal for studies on body size control. The number of somatic nuclei is fixed at 959 in an adult hermaphrodite, and their entire cell lineages were elucidated (Sulston and Horvitz, 1977). There are many mutants with an abnormal body size or shape. For example, several mutants in TGF β signaling factors such as DBL-1/CET-1 (ligand), DAF-4 and SMA-6 (receptor), SMA-2, SMA-3 and SMA-4 (Smad transcriptional factors) are small (Estevez et al., 1993; Savage et al., 1996; Krishna et al., 1999;

Suzuki et al., 1999; Morita et al., 1999). We and others have shown that *egl-4* mutants have a larger body size (Daniels et al., 2000; Fujiwara et al., 2002; Hirose et al., 2003), and that the *egl-4* gene encodes cyclic GMP-dependent protein kinases (L'Etoile et al., 2002; Fujiwara et al., 2002; Hirose et al., 2003). We have developed methods to measure body volume, and to analyze morphology and volume of major organs using a confocal microscope: cell size in the major organs is increased in the *egl-4* mutants, while cell numbers are not. Genetic interaction studies strongly suggest that the DBL-1/TGF β pathway functions downstream of EGL-4 for body size control as the body size of a double mutant carrying *egl-4* and *sma-6* or *dbl-1* mutations is close to that of the single small mutant (Hirose et al., 2003). In contrast to the *egl-4* mutants, three small mutants in the DBL-1 pathway have much smaller cell size and indistinguishable cell numbers in major organs (Nagamatsu and Ohshima, 2004). We have also shown that cGMP downregulates body size through EGL-4 (Nakano et al., 2004).

Here, we present studies on the *sma-5* gene. Its mutant is very small, and has additional phenotypes that are not seen in the mutants of the DBL-1/TGF β signaling factors. Our findings, based on the identification of the *sma-5* gene encoding a MAP kinase homolog, provide novel and interesting insights into the mechanisms that control body size.

Materials and methods

Strains and culture of *C. elegans*

Bristol strain N2 was used as the standard wild-type strain. FK312 *sma-5(n678)* was made by backcrossing three times MT3353 *egl-15(n489) sma-5(n678)* obtained from CGC with N2 and selecting a non-Egl line. tm448 was isolated using UV-TMP mutagenesis (Gengyo-Ando and Mitani, 2000). The handling of *C. elegans* strains was performed as described previously (Brenner, 1974; Sulston and Hodgkin, 1988).

Measurement of body sizes

Total body volume, body length and diameters of a worm were measured as described (Hirose et al., 2003), but only body volume is shown here.

Transgenic animals

Microinjection of DNA was carried out as described (Mello et al., 1991). Total concentration of the DNA at injection was adjusted to 100 µg/ml. A pPDW06-1a, pPDW06-9 or pPDW06-c GFP reporter construct was injected alone at 100 µg/ml into *sma-5* mutant animals, and at 50 µg/ml with 50 µg/ml of Bluescript SK+ into N2. Plasmid DNAs or PCR fragments for organ size analysis or rescue were injected at 50 µg/ml together with 50 µg/ml of *kin-8::gfp* (Koga et al., 1999) as a marker, at 50 µg/ml of *dss-1p::gfp* or 20 µg/ml of *col-19p::gfp* (Hirose et al., 2003) with 30 µg/ml of Bluescript SK+.

PCR fragments and plasmid construction

W06B3.2 PCR fragments of 6.7 kb used for rescue were amplified with pfu-turbo polymerase kit (Stratagene) with the primers W06B3.2-sense (AACGTGTACGGAACCGGAAA) and W06B3.2-3'UTR4 (TCTGAGTTCACACTACGTCTGC) from the wild-type genome. The PCR fragments contain the entire coding region of W06B3.2, a promoter region of 1.6 kb for W06B3.2c and a 3' untranslated region of 1.8 kb. They were purified by QIAquick PCR Purification Kit (Qiagen).

We prepared three types of gene fusions of GFP and W06B3.2. pPDW06-1a, which is practically a promoter fusion, was prepared by amplifying 1.6 kb sequence upstream of the predicted initiation codon and 14 bp of coding sequence of W06B3.2c. For pPDW06-9, 1.6 kb upstream sequence and the entire coding region of W06B3.2a/c were amplified as above. A *Pst*I site and a *Sal*I site engineered into PCR primers were used to insert the amplified products into the GFP vector pPD95.77 (A. Fire). pPDW06-c was prepared by amplifying 4.9 kb sequence upstream of the 5' UTR region of W06B3.2a (exon-1). A *Pst*I site engineered into PCR primers were used to insert the amplified products into the GFP vector pPD95.75.

The promoters used in tissue-specific expression of *sma-5* cDNA included *dss-1p* (for intestine) (Hirose et al., 2003), *vha-1p* (for excretory cell) (Oka et al., 1997), *vha-7p* (for hypodermis) (Oka et al., 2001) and 1.6 kb *sma-5* promoter for W06B3.2c as a control. The entire coding region except for termination codon of a *sma-5* cDNA corresponding to W06B3.2c was amplified by PCR with yk506c3 clone (Y. Kohara) as the template. The cDNA and each of the

promoters were inserted into vector pPD49.26 (A. Fire) with one of the following primer sets: *dss-1p-f*, 5'-TTCTGCAGGCTCCGAGGACGAGGAGAAA-3'; *dss-1p-b*, 5'-TTCTGCAGTTCGACTGGAAATAGGCTGA-3'; *vha-1p-f*, 5'-TTCTGCAGCGAAGAGGATCCGTTT-3'; *vha-1p-b*, 5'-TTCTGCAGACCTGAAACATCTGAGTGC-3'; *vha-7p-f*, 5'-AAAACCTGCAGCGACAGGAAATTTGTGAGAAG-3'; *vha-7p-b*, 5'-AAAACCTGCAGCAGATTACGTCGTTGGTGGGA-3'; *sma-5p-f*, 5'-AAAACCTGCAGCCAAGTTGGCGGAAAGAGC-3'; *sma-5p-b*, 5'-AAAACCTGCAGTGATGTGATGGGATCCTTTG-3'.

For amplification by PCR, an ExTaq kit (Takara) was used. A *Pst*I site and a *Sal*I site engineered into PCR primers were used to insert the amplified products into the GFP vector pPD95.77.

Alignment of SMA-5

A homology search was carried out at <http://blast.genome.ad.jp/>, and alignment was done on the web site http://npsa-pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=npsa_clustalw.html.

Measurement of organ sizes

Volumes of hypodermis, intestine or muscles of worms shown in Table 1 were obtained by YN with analysis of transgenic worms expressing GFP specifically in each organ with Zeiss LSM-410 confocal microscope, as described (Hirose et al., 2003). To express GFP in hypodermis, intestine and muscles, *col-19p::gfp*, *dss-1p::gfp* and *myo-3p::gfp*, respectively, were introduced to *sma-5(n678)* mutant in this study, as carried out for N2 and *egl-4* mutants previously (Hirose et al., 2003). Intestinal or hypodermal volume measurement shown in Fig. 7 was carried out essentially as described previously (Hirose et al., 2003), but using Zeiss LSM-510 (NLO) laser-scanning fluorescent microscope equipped with Zeiss Axiovert 200M microscope using 488 nm Ar laser with 50-60% output and 10-50% transmission depending on fluorescent intensity of the sample. PlanApochromat 20×/0.75 objective lens was used. Detector gain values used for the measurement were adjusted by adding 100-140 to, and depending on, the values indicated by Find menu so as to get consistent volumes obtained by LSM-410 or body volumes obtained as described before. Amplitude offset parameter was chosen so as to remove the black image background completely using Range indicator. Images of 512×512 pixels were obtained at 1 µm intervals. Other procedures were as described previously. Transgenic lines used for measurement were obtained as described by Nakano et al. (Nakano et al., 2004).

Measurement of nuclear or cell numbers and analysis of DNA contents

The procedures for measurement of intestinal or hypodermal nuclei and body wall muscle cells were described previously (Nagamatsu and Ohshima, 2004), except that the power of two photon Mai-Tai laser was increased manually from 20 to 80% during the analysis for determination of nuclear DNA contents. Seam cell numbers were counted under a DIC microscope. Intestinal cell numbers were measured in transgenic lines expressing *flr-1::gfp/nls* (pMTG24-5) (Take-uchi et al., 1998).

Table 1. Volumes of hypodermis, intestine and muscles of 4-day-old adults

	Strain	Genotype	Volume (nl) (mean±s.d.)	Relative value of the mean (%)	Number of worms examined
Intestine	FK290	<i>Ex[dss-1p::gfp]</i>	0.89±0.24	100	21
	FK340	<i>sma-5; Ex[dss-1p::gfp]</i>	0.20±0.08	23	17
Hypodermis	FK336	<i>Ex[col-19p::gfp]</i>	1.15±0.32	100	20
	FK383	<i>sma-5; Ex[col-19p::gfp]</i>	0.53±0.20	46	10
Muscles	FK254	<i>Ex[myo-3p::gfp]</i>	0.73±0.16	100	11
	FK239	<i>sma-5; Ex[myo-3p::gfp]</i>	0.31±0.11	43	28

Analysis of protein contents

Total protein contents of 2-day-old animals of the wild type and the *sma-5* mutant were measured as described (Nagamatsu and Ohshima, 2004).

Results

Phenotypes of *sma-5(n678)* mutant

The *sma-5(n678)* mutant has three visible phenotypes: small body size (Fig. 1B), very slow growth (Fig. 2), and irregular distribution and less dark color or density of intestinal granules (Fig. 1E). These phenotypes other than the small size are clearly different from those of the small mutants of the DBL-1/TGF β pathway such as *sma-2*, *sma-3*, *sma-4* and *sma-6* (Savage et al., 1996; Krishna et al., 1999). The body volume of the *sma-5* mutant is 1-1.5 nl or one-fifth to one-third of that of the wild type (about 4.5 nl) in 2- to 4-day old adults. It takes 5 or more days to become an adult (Fig. 2). Although larval development of the *sma-5* mutant is significantly slower than that of the wild type, larval lethality is not significant, based on a survival curve (data not shown). The lifespan of the mutant is shorter than that of the wild type [10.5 ± 2.5 (s.d.) days versus 14.3 ± 4.7 days]. The number of eggs laid by a hermaphrodite is significantly smaller in the *sma-5* mutant than that of the wild type [139 ± 28 (s.d.) versus 255 ± 9.8].

Identification of the *sma-5* gene

sma-5(n678) had been mapped to a region of 0.6 map unit on chromosome X, right of *mes-1* and left of or near *nuc-1* (<http://www.wormbase.org/> and Fig. 3A). Based on this information, we injected YAC and cosmid DNA clones, and found that YAC Y75H1 and cosmid R03B7 (Fig. 3A) could rescue its abnormal phenotypes of the *sma-5* mutant (Fig. 1C; data not shown). R03B7 contains four genes (Fig. 3). Among them, only W06B3.2 (PCR fragments of 6.7 kb) rescued the abnormal phenotypes of *sma-5* (Fig. 2).

Fig. 2. Growth curves of N2, *sma-5(n678)*, *sma-5(tm448)*, *i24-1* (*sma-5(n678); Ex[W06B3.2 genomic gene, kin-8::gfp]*) and *i52-1* (*sma-5(tm448); Ex[sma-5 genomic gene, kin-8::gfp]*). Error bars indicate standard deviations. Number of worms examined for each time point was 8-39.





Fig. 1. DIC microphotographs of an L4 stage animal of N2 (A), *sma-5(n678)* (B) and *sma-5; Ex[Y75H1, kin-8::gfp]* (C). (D-F) Higher magnification views of a part of the worm shown in A-C, respectively. These pictures were taken using an AxioCam CCD camera mounted on Zeiss Axiophot 2.



Body volumes of the rescued lines are much larger than that of *sma-5*, but not as large as that of the wild type. Their growth rate and distribution of intestinal granules are similar to those of the wild type (Fig. 2; Fig. 1F). We found a deletion of about 15 kb in the genome of *sma-5(n678)* (Fig. 3B). The deleted region contains the four genes *C49F5.3*, *C49F5.5*, *C49F5.6* and *C49F5.7* (<http://www.wormbase.org/>), and 226 bp from the 3' end of *W06B3.2*-coding sequence. We prepared PCR fragments of *C49F5.3*, *C49F5.5*, *C49F5.6* and *C49F5.7*, and injected each into the *sma-5* mutant. Those PCR fragments could not rescue the *sma-5* mutant phenotypes (data not shown).

In order to confirm that *W06B3.2* is the *sma-5* gene, we performed RNAi experiments (Fire et al., 1998). We injected dsRNA corresponding to nucleotides from 148 to 901 of *W06B3.2c* into wild-type animals, and observed phenotypes of F1 animals. They exhibited *Sma-5* phenotypes: small body size (Fig. 3C), slow growth and abnormal intestinal granules. In addition, we recently isolated a second allele of *sma-5*, *tm448*, that has 748 bp deletion in *W06B3.2* (Fig. 3B). The *tm448* mutant shows phenotypes similar to those of *sma-5(n678)*: it is small, grows very slowly (Fig. 2) and its intestinal granules are abnormal. As in the case of *sma-5(n678)*, PCR fragments partially rescued its abnormal phenotypes (Fig. 2; data not




Fig. 3. Cloning of the *sma-5* gene, mRNA structure and RNAi experiments. (A) Physical map of the region around *sma-5* gene. The YAC DNA clone, cosmid DNA clones and PCR fragments used for identification of the *sma-5* gene are shown. Thick lines represent regions carrying functional *sma-5* gene. (B) Location of deletions in *W06B3.2* and structure of mRNAs. White and grey rectangles indicate coding and non-coding exons, respectively. (C) RNAi experiments. Average volumes of progeny born after injection of dsRNA of *W06B3.2* into N2 (RNAi-1, 2, 3), control progeny born from a parent injected with water or *sma-5(n678)* mutant worms are shown together with standard deviations. Two-day-old adult animals were used for measurement.

shown). Based on these results, we conclude that W06B3.2 is the *sma-5* gene.

The *sma-5* gene encodes MAP kinase homologues

A recent version of WormBase describes W06B3.2a (Fig. 3B) and W06B3.2b. We sequenced cDNAs obtained by RT-PCR and cDNA clones yk506c3 and yk1526e1.3 obtained from Y. Kohara, to identify two alternative forms of the mRNA (a and b) that differ at the 5' ends. The open reading frame (ORF) or coding sequence of W06B3.2a exactly matches that of our 'a' mRNA (498 amino acids), but W06B3.2a has an extra non-coding exon 3.6 kb upstream of the initiation codon (exon 1 in Fig. 3B). W06B3.2b carrying an ORF lacking exon 9 does not match our mRNA a or b. The structures of our a and b mRNA are shown in Fig. 3B as W06B3.2c and W06B3.2d. All these mRNAs encode homologs of a mammalian MAP kinase BMK1/ERK5/MAPK7 (Fig. 4 for W06B3.2a or W06B3.2c) (Lee et al., 1995; Zhou et al., 1995). *C. elegans* W06B3.2a has 38% amino acid identity and 60% similarity with human MAPK7/ERK5.

Expression patterns of the *sma-5* gene

To examine the expression pattern of the *sma-5* gene, we prepared three GFP reporter constructs. pPDW06-1a expresses a GFP fusion with N-terminal five amino acids of W06B3.2a/c under a control of promoter for W06B3.2c of 1.6 kb. GFP expression was found in intestine (Fig. 5A,C,E,F) and excretory cell (Fig. 5E,F), in all stages of a transgenic line carrying extrachromosomal arrays of pPDW06-1a. In the intestine, the four most anterior cells show stronger GFP expression, although entire intestine is fluorescent. The expression in the excretory cell (White, 1988) was confirmed by comparison with the expression pattern of *vha-1p::gfp* that is predominantly expressed in the excretory cell (Oka et al., 1997). GFP in the excretory cell is seen continuously along the lateral lines for most of the length of the worm (data not shown). Weak expression in hypodermis is also seen (Fig. 5F). A second GFP fusion construct pPDW06-9, which contains the same promoter for W06B3.2c and the entire genomic region of W06B3.2a/c except for the termination codon, rescued the phenotypes of the *sma-5* mutant, and looks to be expressed in the same regions as was pPDW06-1a (Fig. 5D for intestinal expression). This fusion protein is localized throughout the intestine. The third construct pPDW06-c carries the 4.9 kb sequence upstream of exon 1 and a GFP gene. GFP in this promoter fusion is expressed in hypodermis and pharynx (Fig. 5G,H).




Fig. 4. Alignment of amino acid sequences of W06B3.2a/c (upper line) and human MAPK7/ERK5 (lower line). A vertical line indicates identical amino acid, a colon indicates strong similarity and a dot indicates weak similarity between amino acids. A broken line indicates absence of corresponding amino acids.

Sizes of major organs and their cells of the *sma-5* (*n678*) mutant

Because the *sma-5* mutant has a markedly reduced body size in adults, the number or the size of cells in major organs is probably decreased. We analyzed morphology of three major organs in the adults. To do this, a whole transgenic animal expressing GFP specifically in intestine, hypodermis or muscles was examined using a confocal laser-scanning microscope. Based on a series of sectional fluorescent images, a 3D image was reconstructed and its volume was calculated with an image-processing system, as described in the Materials and methods. Fig. 6 shows examples of 3D images of these organs in the *sma-5*(*n678*) mutant. The morphology of hypodermis, intestine and muscles in 2-day-old adults of the *sma-5* mutant looked normal when compared with those of the wild type that were described earlier (Hirose et al., 2003).

Results of volume measurement are presented in Table 1. The numbers of cells or nuclei in these organs were also measured (Table 2). The volume of whole intestine decreased




Fig. 5. Expression patterns of *sma-5::gfp* reporter genes. (A-C) A dorsal fluorescent image (A), a DIC image (B) and the merge of A and B (C) of an entire L4 animal transgenic for pPDW06-1a carrying a promoter for W06B3.2c. (D) A merge of dorsal fluorescent and DIC images of a young adult expressing a SMA-5/GFP fusion protein in intestine from pPDW06-9. (E) A confocal microscopic, dorsal/ventral image of a part of the body showing H-shaped excretory cell and the anterior end of intestine in an L4 worm expressing pPDW06-1a. (F) A similar confocal microscopic image, but color-coded depending on the depth, showing intestine (green), excretory cell (blue or yellow), and nuclei and faint cytoplasm of hypodermis (blue). (G,H) Lateral confocal microscopic images of an L2 worm transgenic for pPDW06-c carrying a promoter for W06B3.2a that expresses GFP in hypodermis (G) and pharynx (H).

Table 2. Numbers of cells and nuclei in 2-day-old adults

	Genotype	Number (mean±s.d.)	Relative value of the mean (%)	Number of worms examined
Intestinal cells (L1 stage)	Wild type (N2)	18±0.8	100	7
	<i>sma-5(n678)</i>	18±0.6	100	10
Intestinal nuclei	Wild type (N2)	32±1.5	100	15
	<i>sma-5(n678)</i>	27±2.4*	84	11
	<i>sma-5; Ex[pPDW06-9][†]</i>	31±1.4	97	14
Hypodermal seam cells/side	Wild type (N2)	16.5±1.3	100	12
	<i>sma-5(n678)</i>	16.2±0.8	98	5
Hypodermal nuclei/side	Wild type (N2)	89±10	100	6
	<i>sma-5(n678)</i>	69±4*	76	8
Body wall muscle cells in two quadrants	Wild type (N2)	47±0.69	100	20
	<i>sma-5(n678)</i>	46±1.1	98	20

*Significantly different from the wild-type value ($P < 0.01$, t -test).

[†]pPDW06-9 plasmid contains full length of the *sma-5* genomic gene fused with GFP gene.

to 23% of the wild-type value in the *sma-5* mutant. Although the average number of intestinal nuclei slightly decreased in the mutant, the number of intestinal cells was the same as that of the wild type (Table 2). Therefore, intestinal cells in the *sma-5* mutant must be much smaller than those in the wild type. The number of intestinal nuclei was recovered to nearly the same as that of the wild type by introduction of the *sma-5* gene (Table 2). The volume of hypodermis decreased to 46% in the mutant. Most of the hypodermis is occupied by a single, giant syncytium *hyp7* that covers the nearly entire body and contains 133 nuclei out of the 188 hypodermal nuclei in total (White, 1988). In the *sma-5* mutant, therefore, the volume of this *hyp7* syncytium should be decreased approximately to half. Although the number of hypodermal seam cells in the *sma-5* mutant is very close to that in the wild type, the number of total hypodermal nuclei in the mutant is decreased to 76% of that of the wild type (Table 2). Volume of the muscles expressing *myo-3p::gfp* (body wall muscles, vulval, uterine and intestine-associated muscles) (Okkema et al., 1993) was decreased to 43% of that of the wild type (Table 1). A great majority of those muscle cells consist of body wall muscle cells, and their number was not changed in the mutant (Table 2). These results suggest that the *sma-5* mutant has the same number of cells, and that the cell size is much smaller.




Fig. 6. Three-dimensional reconstructed images of hypodermis (A), intestine (B) and muscles (C) in the *sma-5(n678)* background. Scale bar: 200 μ m.

Effect of *sma-5* gene expression in the *sma-5(n678)* mutant on body and organ sizes

To elucidate where the *sma-5* gene expression is required for body size control, we examined the effect of expression of extrachromosomal *sma-5* cDNA under a tissue-specific promoter or a *sma-5* promoter, as well as that of the genomic *sma-5* gene (Fig. 7). The results are presented as bars and percentages showing body volume, intestinal or hypodermal volumes relative to those in the wild-type background. As to the total body size, expression of the 6.7 kb genomic gene carrying promoters for W06B3.2c and W06B3.2d, or *sma-5* cDNA under the *sma-5* promoter for W06B3.2c, led to increase of more than twice of the volume of the *sma-5* mutant. Among the specific promoters examined, *vha-7* promoter specific to hypodermis is most effective for recovery of the body volume, and *vha-1* promoter, which predominantly directs expression in excretory cell, has a small but significant effect, and *dss-1* promoter specific to intestine is not effective. For organ sizes, cDNA expression in hypodermis leads to increase in the volume of hypodermis and intestine. The expression in excretory cell increases intestinal volume.

Analysis of DNA content and total protein content

To elucidate the mechanisms of cell size decrease in the *sma-5* mutant, we have analyzed chromosomal ploidies and total protein content in the wild type and the mutant. Chromosomal ploidy is a well known, universal control factor for cell size (Conlon and Raff, 1999). For analysis of chromosomal ploidy, we examined intestinal and neuronal nuclei of worms stained with 4',6-diamidino-2-phenylindole (DAPI) as described in the Materials and methods. Intestinal nuclei in the wild-type *C. elegans* become 32C by the adult stage, which is the highest ploidy in the wild type, while neuronal nuclei remain diploid (Hedgecock and White, 1985). In addition, intestinal cells show the greatest volume reduction in the *sma-5* mutant. Thus, chromosomal ploidy in intestine of the *sma-5* mutant could possibly be less in the *sma-5* mutant than those in the wild type. Average intestinal chromosomal ploidy of the *sma-5* mutant adult was estimated to be 34, assuming that neuronal nuclei are diploid (as in the wild type) and the value in the wild type was 35. Because these values are very close, we conclude that intestinal chromosomal ploidy is not changed in the *sma-5* mutant.

We were also interested to know whether the level of general gene expression is altered in this mutant. Total protein content of a worm should be a good measure of the level of general gene expression. Indeed, the protein content of the *sma-5* mutant was only 18% of that of the wild type (0.16 compared with 0.88 μ g/worm).

Discussion

Identification of the *sma-5* gene

The *sma-5(n678)* mutant is small and has smaller but almost the same number of cells. We found that the *sma-5* gene is W06B3.2, which encodes homologs of mammalian MAP kinase MAPK7/BMK1/ERK5. W06B3.2a and W06B3.2c encode the same protein of 498 amino acids (Fig. 3B). They share expression in hypodermis, but are also expressed in different regions (the former in pharynx, and the latter in

intestine and excretory cell). The endogenous *sma-5* gene is probably expressed in all of these sites. As cDNA corresponding to W06B3.2c is functional in our assay and W06B3.2a has the same ORF, W06B3.2a should also be functional. We have not examined whether W06B3.2d lacking exon 2 and W06B3.2b lacking exon 9 have functions.

Extrachromosomal arrays of Y75H1, R03B7 or W06B3.2 PCR fragments rescued the abnormal phenotypes of the *sma-5* mutant to the same extent. The rescue of the body size by any of these was not complete, although growth rate and irregular distribution of intestinal granules were almost completely rescued. We prepared a transgenic line *it22-1::sma-5; In[W06B3.2 PCR fragment, kin-8::gfp]* by UV radiation (Mitani, 1995) in which the extrachromosomal arrays of the PCR fragments were integrated. But that integrated line is as large as the extrachromosomal transgenic lines. A plausible reason for the incomplete rescue of the *sma-5* body size by W06B3.2 may be that the pattern, strength or timing of the exogenous gene expression is somewhat different from those of the endogenous *sma-5* gene.

sma-5 functions in post-embryonic development

We measured the volume of eggs (embryos) laid by wild-type and the *sma-5(n678)* mutant. There was little difference between them (both were ~ 0.03 nl). In addition, there was little difference in morphology and volume of L1 larvae about 2 hours after hatch between them. *sma-5::gfp* was expressed in some embryos, but it is not clear whether *sma-5* expression is necessary for embryonic development. *sma-5::gfp* expression is seen in all larval stages, which suggests that it is required for normal larval development from L1 stage.

The *sma-5* gene regulates body size mainly through control of cell growth

BMK1/ERK5/MAPK7 is the newest subfamily of the MAP kinase family in mammals, and it has some characteristic features: a large C-terminus and a unique loop 12 sequence (Lee et al., 1995). Mammalian BMK1/ERK5 was shown to be activated by oxidative stress, hyperosmolarity and several growth factors, including epidermal growth factor and nerve growth factor (Abe et al., 1996; Chao et al., 1999; Lee et al., 1995; Zhou et al., 1995; Kato et al., 1998; Kamakura et al., 1999). It has also been reported that BMK1/ERK5 regulates cell proliferation and cell cycle in cultured cells (Kato et al., 1998; Chao et al., 1999). Recent reports have demonstrated that the homozygous deletion of BMK1/ERK5 results in embryonic




Fig. 7. Effect of expression of extrachromosomal *sma-5* genomic gene (second group of columns) or *sma-5* cDNA under the indicated promoter (lower groups of columns) in the *sma-5* (*n678*) mutant on body and organ volume in 2-day-old adults. Body volumes relative to those of the wild-type body volume (white bar), and intestinal volumes (gray bar) or hypodermal volumes (black bar) relative to those of the *dss-1::gfp* or *col-19p::gfp* transgenic lines in the wild-type background are shown by bars. The top group of columns show the results of the *sma-5* (*n678*) mutant. T-shaped bars represent s.e.m., which was calculated by the formula $(fDx^2/y^2 + x^2fDy^2/y^4)^{1/2}/n^{1/2}$ where x and fDx are mean and s.d. of the volume of the indicated strain, and y and fDy are those of the wild-type volume (Bevington and Robinson, 2003). The smaller of the numbers of worms examined for the indicated and the wild-type worms was taken as n . An asterisk indicates significant difference in t -tests ($P \leq 0.05$) from the value for the *sma-5* mutant. One-hundred percent (wild-type volume) corresponds to 4.39 ± 0.41 nl, 0.88 ± 0.068 nl and 1.01 ± 0.20 nl for body, intestinal and hypodermal volumes, respectively. Hypodermal volume of a worm expressing *sma-5* cDNA under *dss-1* promoter was not obtained because a corresponding transgenic line was not obtained.

lethality in mice with extra-embryonic vascular and embryonic cardiovascular defects (Regan et al., 2002; Sohn et al., 2002).

As the *sma-5* mutant has significantly smaller but indistinguishable numbers of cells, we propose that SMA-5 regulates body size mainly through control of cell growth. Measurement of embryonic size described in the Results and growth curves shown in Fig. 2 for larvae and adults suggest that embryonic cell sizes in the *sma-5* mutant are similar to those of the wild type. They also suggest that cell growth in the mutant is much slower in larval development so that cell proliferation is slower and that final cell sizes are smaller. The results of measurement of hypodermal and intestinal nuclear numbers suggest that SMA-5 also has a limited function in nuclear proliferation in these organs. As postembryonic hypodermal nuclei in the large hyp7 syncytium are born by fusion with postembryonic hypodermal cells, SMA-5 has also a function in cell proliferation. Thus, the function of SMA-5 in *C. elegans* seems to be somewhat different from that of BMK1/ERK5 in mammalian cells, but has a common function in cell proliferation. It is not clear whether BMK1/ERK5 controls body size in mammals because the knockout mice are lethal (Regan et al., 2002; Sohn et al., 2002). By contrast, the *tm448* mutant carrying a large deletion in the *sma-5* gene should be a null mutant, but it is viable and has quite similar

characteristics as the *sma-5(n678)* mutant. Thus, our results indicating the function of SMA-5 in body size control are novel and interesting.

Site and mode of action of the *sma-5* gene

Based on the results presented in Fig. 7, the hypodermis seems to be the most important site of *sma-5* gene expression for the control of body and organ size. Although promoter for W06B3.2c drives only weakly visible expression in hypodermis, the far upstream promoter for W06B3.2a probably makes the expression stronger for the endogenous *sma-5* gene. The importance of hypodermal expression for body size control was also reported previously for *sma-6* (Yoshida et al., 2001), *sma-3* (Wang et al., 2002) and *egl-4* (Nakano et al., 2004). Although expression of *sma-5* in the excretory cell may be interesting, we do not have any evidence to see whether the same mechanism works there as in hypodermis. Because the expression in hypodermis increases hypodermal volume, and both expression in hypodermis and that in excretory cell increase intestinal volume, the *sma-5* gene can function both organ- or cell-autonomously and non-autonomously, as has been shown for the *egl-4* gene (Nakano et al., 2004). The reason why intestinal expression of the cDNA failed to increase intestinal volume is not clear.

Conserved features of body size control in *C. elegans*

We notice two conserved characteristics in the body size mutants in *C. elegans* so far analyzed. First, little or no changes in cell numbers from those in the wild type are seen in the *sma-5* mutant analyzed here – the three small mutants of the DBL-1/TGF β pathway and a *sma-1* mutant (Nagamatsu and Ohshima, 2004), as well as *egl-4* large mutants (Hirose et al., 2003). These results may be related to the small number of somatic cells and rather rigid cell lineages in *C. elegans* (Sulston and Horvitz, 1977), and may suggest that a mutation leading to a significant change in the overall cell number is hard to obtain or is lethal. Although extra cell divisions were observed in *cul-1/lin-19* or *lin-23* mutants, they are lethal or sterile (Kipreos et al., 1996; Kipreos et al., 2000). To examine these ideas, further efforts will be required to obtain body size mutants in which cell number is significantly altered. Second, protein contents are decreased in all the small mutants analyzed roughly in proportion to their reduced body size (this report) (Nagamatsu and Ohshima, 2004). We propose that the level of general protein expression has an important relation to the cell size in *C. elegans*. A close link between cell size and protein and ribosome synthesis has been suggested in yeast and other organisms (Jorgensen et al., 2002; Saucedo and Edgar, 2002).

Some nematode strains were obtained from the Caenorhabditis Genetic Center, which is funded by a grant from the National Institute of Health for Research Resources. We thank A. Fire for vectors; Y. Kohara for cDNA clones; T. Oka for *vha-1p::gfp*; K. Ishii and T. Tani for *dss-1::gfp*; T. Ishihara for general support; M. Fujiwara, M. Koga and other members of our laboratory for discussion; M. Fujiwara for critical reading of the manuscript; and M. Ohara for language assistance. This work was supported by The Japan Society for the Promotion of Science (Research for the Future 97L00401) and a grant from the Ministry of Education, Science, Technology, Sports and Culture of Japan to Y.O.

References

- Abe, J., Kusuvara, M., Ulevitch, R. J., Berk, B. C. and Lee, J. D. (1996). Big mitogen-activated protein kinase 1 (BMK1) is a redox-sensitive kinase. *J. Biol. Chem.* **271**, 16586-16590.
- Bevington, P. R. and Robinson, D. K. (2003). In *Data Reduction and Error Analysis for Physical Sciences*, 3rd edn, Chapter 3, p. 41. New York: McGraw-Hill.
- Böhni, R., Riesgo-Escovar, J., Oldham, S., Brogiolo, W., Stocker, H., Andruss, B. F., Beckingham, K. and Hafen, E. (1999). Autonomous control of cell and organ size by CHICO, a *Drosophila* homolog of vertebrate IRS1-4. *Cell* **97**, 865-875.
- Brenner, S. (1974). The genetics of *Caenorhabditis elegans*. *Genetics* **77**, 71-94.
- Brock, D. A. and Gomer, R. H. (1999). A cell-counting factor regulating structure size in *Dictyostelium*. *Genes Dev.* **13**, 1960-1969.
- Chao, T. H., Hayashi, M., Tapping, R. I., Kato, Y. and Lee, J. D. (1999). MEK3 directly regulates MEK5 activity as part of the big mitogen-activated protein kinase 1 (BMK1) signaling pathway. *J. Biol. Chem.* **274**, 36035-36038.
- Conlon, I. and Raff, M. (1999). Size control in animal development. *Cell* **96**, 235-244.
- Daniels, S. A., Ailion, M., Thomas, J. H. and Sengupta, P. (2000). *egl-4* acts through a transforming growth factor- β /SMAD pathway in *Caenorhabditis elegans* to regulate multiple neuronal circuits in response to sensory cues. *Genetics* **156**, 123-141.
- Estevez, M., Attisano, L., Wrana, J. L., Albert, P. S., Massague, J. and Riddle, D. L. (1993). The *daf-4* gene encodes a bone morphogenetic protein receptor controlling *C. elegans* dauer larva development. *Nature* **365**, 644-649.
- Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E. and Mello, C. C. (1998). Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature* **391**, 806-811.
- Fujiwara, M., Sengupta, P. and McIntire, S. L. (2002). Regulation of body size and behavioral state of *C. elegans* by sensory perception and EGL-4 cGMP-dependent protein kinase. *Neuron* **36**, 1091-1102.
- Gengyo-Ando, K. and Mitani, S. (2000). Characterization of mutations induced by ethyl methanesulfonate, UV, and trimethylpsoralen in the nematode *Caenorhabditis elegans*. *Biochem. Biophys. Res. Commun.* **269**, 64-69.
- Hedgecock, E. M. and White, J. G. (1985). Polyploid tissues in the nematode *Caenorhabditis elegans*. *Dev. Biol.* **107**, 128-133.
- Hirose, T., Nakano, Y., Nagamatsu, Y., Misumi, T., Ohta, H. and Ohshima, Y. (2003). Cyclic GMP-dependent protein kinase EGL-4 controls body size and lifespan in *C. elegans*. *Development* **130**, 1089-1099.
- Jorgensen, P., Nishikawa, J. L., Breitkreutz, B. J. and Tyers, M. (2002). Systematic identification of pathways that couple cell growth and division in yeast. *Science* **294**, 395-400.
- Kamakura, S., Moriguchi, T. and Nishida, E. (1999). Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. *J. Biol. Chem.* **274**, 26563-26571.
- Kato, Y., Tapping, R. I., Huang, S., Watson, M. H., Ulevitch, R. J. and Lee, J. D. (1998). Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. *Nature* **395**, 713-716.
- Kipreos, E. T., Lander, L. E., Wing, J. P., He, W. W. and Hedgecock, E. M. (1996). *cul-1* is Required for cell cycle exit in *C. elegans* and identifies a novel gene family. *Cell* **85**, 829-839.
- Kipreos, E. T., Gohel, S. P. and Hedgecock, E. M. (2000). The *C. elegans* F-box/WD-repeat protein LIN-23 functions to limit cell division. *Development* **127**, 5071-5082.
- Koga, M., Take-uchi, M., Tameishi, T. and Ohshima, Y. (1999). Control of DAF-7 TGF- β expression and neuronal process development by a receptor tyrosine kinase KIN-8 in *Caenorhabditis elegans*. *Development* **126**, 5387-5398.
- Krishna, S., Maduzia, L. L. and Padgett, R. W. (1999). Specificity of TGF β signaling is conferred by distinct type I receptors and their associated SMAD proteins in *Caenorhabditis elegans*. *Development* **126**, 251-260.
- Lee, J. D., Ulevitch, R. J. and Han, J. (1995). Primary structure of BMK1: a new mammalian map kinase. *Biochem. Biophys. Res. Commun.* **213**, 715-724.
- Leever, S. J., Weinkove, D., MacDougall, L. K., Hafen, E. and Waterfield, M. D. (1996). The *Drosophila* phosphoinositide 3-kinase Dp110 promotes cell growth. *EMBO J.* **15**, 6584-6594.
- L'Etoile, N. D., Coburn, C. M., Eastham, J., Kistler, A., Gallegos, G. and

- Bargmann, C. I.** (2002). The cyclic GMP-dependent protein kinase EGL-4 directs olfactory adaptation in *C. elegans*. *Neuron* **36**, 1079-1089.
- Massague, J.** (2000). How cells read TGF- β signals. *Nat. Rev. Mol. Cell. Biol.* **1**, 169-178.
- Mello, C. C., Kramer, J. M., Stinchcomb, D. and Ambros, V.** (1991). Efficient gene transfer in *C. elegans*: extrachromosomal maintenance and integration of transforming sequences. *EMBO J.* **10**, 3959-3970.
- Mitani, S.** (1995). Genetic regulation of *mec-3* gene expression implicated in the specification of the mechanosensory neuron cell types in *Caenorhabditis elegans*. *Dev. Growth Diff.* **37**, 551-557.
- Morita, K., Chow, K. L. and Ueno, N.** (1999). Regulation of body length and male tail ray pattern formation of *Caenorhabditis elegans* by a member of TGF- β family. *Development* **126**, 1337-1347.
- Nagamatsu, Y. and Ohshima, Y.** (2004). Mechanisms for the control of body size by a G-kinase and a downstream TGF β signal pathway in *Caenorhabditis elegans*. *Genes Cells* **9**, 39-47.
- Nakano, Y., Nagamatsu, Y. and Ohshima, Y.** (2004). cGMP and a germ-line signal control body size in *C. elegans* through cGMP-dependent protein kinase EGL-4. *Genes Cells* **9**, 773-779.
- Oka, T., Yamamoto, R. and Futai, M.** (1997). Three *vha* genes encode proteolipids of *Caenorhabditis elegans* vacuolar-type ATPase. *J. Biol. Chem.* **272**, 24387-24392.
- Oka, T., Toyomura, T., Honjo, K., Wada, Y. and Futai, M.** (2001). Four subunit isoforms of *Caenorhabditis elegans* vacuolar H⁺-ATPase. Cell-specific expression during development. *J. Biol. Chem.* **276**, 33079-33085.
- Okkema, P. G., Harrison, S. W., Plunger, V., Aryana, A. and Fire, A.** (1993). Sequence requirements for myosin gene expression and regulation in *Caenorhabditis elegans*. *Genetics* **135**, 385-404.
- Palmiter, R. D., Brinster, R. L., Hammer, R. E., Trumbauer, M. E., Rosenfeld, M. G., Birnberg, N. C. and Evans, R. M.** (1982). Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone fusion genes. *Nature* **300**, 611-615.
- Patterson, G. I. and Padgett, R. W.** (2000). TGF β -related pathways. Roles in *Caenorhabditis elegans* development. *Trends Genet.* **16**, 27-33.
- Regan, C. P., Li, W., Boucher, D. M., Spatz, S., Su, M. S. and Kuida, K.** (2002). Erk5 null mice display multiple extraembryonic vascular and embryonic cardiovascular defects. *Proc. Natl. Acad. Sci. USA* **99**, 9248-9253.
- Saucedo, L. J. and Edgar, B. A.** (2002). Why size matters: altering cell size. *Curr. Opin. Genet. Dev.* **12**, 565-571.
- Savage, C., Das, P., Finelli, A. L., Townsend, S. R., Sun, C. Y., Baird, S. E. and Padgett, R. W.** (1996). *Caenorhabditis elegans* genes *sma-2*, *sma-3*, and *sma-4* define a conserved family of transforming growth factor β pathway components. *Proc. Natl. Acad. Sci. USA* **93**, 790-794.
- Sohn, S. J., Sarvis, B. K., Cado, D. and Winoto, A.** (2002). ERK5 MAPK regulates embryonic angiogenesis and acts as a hypoxia-sensitive repressor of vascular endothelial growth factor expression. *J. Biol. Chem.* **277**, 43344-43351.
- Sulston, J. E. and Horvitz, H. R.** (1977). Post-embryonic cell lineages of the nematode, *Caenorhabditis elegans*. *Dev. Biol.* **56**, 110-156.
- Sulston, J. and Hodgkin, J.** (1988). Methods. In *The Nematode Caenorhabditis elegans* (ed. W. B. Wood and the Community of *C. elegans* Researchers), pp. 587-606. Cold Spring Harbor: Cold Spring Harbor Laboratory.
- Suzuki, Y., Yandell, M. D., Roy, P. J., Krishna, S., Savage-Dunn, C., Ross, R. M., Padgett, R. W. and Wood, W. B.** (1999). A BMP homolog acts as a dose-dependent regulator of body size and male tail patterning in *Caenorhabditis elegans*. *Development* **126**, 241-250.
- Take-uchi, M., Kawakami, M., Ishihara, T., Amano, T., Kondo, K. and Katsura, I.** (1998). An ion channel of the degenerin/epithelial sodium channel superfamily controls defecation rhythm in *Caenorhabditis elegans*. *Proc. Natl. Acad. Sci. USA* **95**, 11775-11780.
- Wang, J., Tokarz, R. and Savage-Dunn, C.** (2002). The expression of TGF β signal transducers in the hypodermis regulates body size in *C. elegans*. *Development* **129**, 4989-4998.
- White, J.** (1988). The anatomy. In *The Nematode Caenorhabditis elegans* (ed. W. B. Wood and the Community of *C. elegans* Researchers), pp. 81-122. Cold Spring Harbor: Cold Spring Harbor Laboratory.
- Yoshida, S., Morita, K., Mochii, M. and Ueno, N.** (2001). Hypodermal expression of *Caenorhabditis elegans* TGF- β type I receptor SMA-6 is essential for the growth and maintenance of body length. *Dev. Biol.* **240**, 32-45.
- Zhou, G., Bao, Z. Q. and Dixon, J. E.** (1995). Components of a new human protein kinase signal transduction pathway. *J. Biol. Chem.* **270**, 12665-12669.